Skip to main content

Table 2 Characteristics of the patients with hypertension tested for COVID-19

From: Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective

  COVID-19 (−) COVID-19 (+) Difference (95% CI)
Age    80.6791***
  < 60 22,850 (0.97) 665 (0.03)  
 61–69 15,609 (0.97) 514 (0.03)  
 70–79 17,899 (0.98) 418 (0.02)  
  ≥ 80 17,258 (0.98) 314 (0.02)  
Sex    56.6345***
 Male 38,922 (0.98) 844 (0.02)  
 Female 34,694 (0.97) 1067 (0.03)  
Diabetes Mellitus    29.5498***
 Yes 30,184 (0.97) 902 (0.03)  
 No 43,432 (0.98) 1009 (0.02)  
Cardiovascular disease    2.9933
 Yes 69,012 (0.97) 1810 (0.03)  
 No 4604 (0.98) 101 (0.02)  
Cerebrovascular disease    26.7711***
 Yes 59,392 (0.97) 1632 (0.03)  
 No 14,224 (0.98) 279 (0.02)  
Ischemic heart disease    52.4329***
 Yes 61,686 (0.97) 1719 (0.03)  
 No 11,930 (0.98) 192 (0.02)  
COPD    53.0971***
 Yes 68,791 (0.97) 1865 (0.03)  
 No 4825 (0.99) 46 (0.01)  
Malignancy    180.4433***
 Yes 59,384 (0.97) 1775 (0.03)  
 No 14,232 (0.99) 136 (0.01)  
Renal replacement therapy    74.6484***
 Yes 69,301 (0.97) 1888 (0.03)  
 No 4315 (0.99) 23 (0.01)  
ACEIs or ARBs    0.0028
 Yes 12,785 (0.97) 331 (0.03)  
 No 60,831 (0.97) 1580 (0.03)  
  1. * P < .05; ** P < .01; *** P < .001
\